Even though the first patents for Nuedexta (dextromethorphan and quinidine) have expired, no generic versions of this medication are available at this time. However, there is another patent for Nuedexta, which is set to expire in January 2016. It's possible that this patent is protecting brand-name Nuedexta from generic competition.
Nuedexta™ (dextromethorphan and quinidine) is a prescription medication licensed to treat a neurological condition known as pseudobulbar affect (PBA). People with this condition have sudden, involuntary outbursts of crying or laughing, even when there is nothing to laugh or cry about.
This medication is made by Patheon, Inc., for Avanir Pharmaceuticals, Inc. It is currently under the protection of patents that prevent any generic Nuedexta from being manufactured in the United States.
The first patents for Nuedexta expired in June 2011 and March 2012, yet no generic versions are available. This suggests that later-expiring patents are still protecting the drug from generic competition. The next Nuedexta patent will expire in January 2016. At this point, this is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Nuedexta uses. Once the medication goes off-patent, there may be several companies that manufacture a generic Nuedexta drug.
No, dextromethorphan and quinidine are the active ingredients in Nuedexta, not generic versions of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.